Table 7.
Lung CT scan analysis.
| Control | Foralumab/Dexa | Foralumab | ||
|---|---|---|---|---|
| Worsened | 0/14 | 1/10 | 0/12 | |
| Stable | 10/14 | 2/10 | 2/12 | |
| Improved | 3/8 | 1/8 | 5/12 | |
| Marked Improvement* | 1/8 | 6/8 | 5/12 | |
Patients were classified as worsened if they increased by one or more stage, improved if they decreased by one stage and as having marked improvement if they decreased by 2 or more stages.
Two patients in the control group and 1 in Foralumab/Dexa group did not undergo lung CT at day 13 and thus are not part of the analysis.
Six patients in the control group and 2 in the Foralumab/Dexa group had no lung involvement on day -2 and thus were not able to improve. They are not counted in the improved categories.
*p=0.01, Control vs. Foralumab/Dexa and p=0.04, Control vs. Forlumab/Dexa+Foralumab, chi-square analysis.